The Axsome management team will provide an overview of SYMBRAVO and anticipated commercial plans. The presenters will be available to answer questions at the end of the presentation. To access the ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigin ...

Fact-Check: A video showing a man delivering a speech is being shared to falsely claim that the founder of Himalaya urged ...

These peptides have shown promise in inhibiting the aggregation of amyloid beta, potentially preventing plaque formation. Repurposing Ayurvedic Drug for Modern Neurodegenerative Treatment In an ...

Hi, %{firstName}% Games Car rental Gayle Hays has paid north of $8,000 a year for her and her husband’s prescription medications. One drug alone has cost the couple nearly $7,000 annually in ...

This way, clinical trials can be made more effective and avoid the pitfalls that masked the efficacy of the drug. However, the pharmaceutical industry has no interest in going back to plant-based ...

Medicare adds popular weight loss and diabetes drugs to negotiation list, potentially saving billions. New law allows Medicare to haggle over prices, with 25 drugs now accounting for a third of ...

Minovacca plans to hire Nebraska students whose work will drive the company toward a major milestone: submitting an Investigational New Drug Application to the U.S. Food and Drug Administration ...

In his excellent article on “Poor-quality and counterfeit medicines and unnecessary drugs” (The Island 06 January, 2025), Professor Saman Gunatilake wrote, “However, in our country what are assumed to ...

But his efforts to stay alive indefinitely seem to have been scuppered by an anti-aging drug which could in fact have the opposite effect. Called Project Blueprint, he sells his own supplements ...

The three largest drug middlemen inflated the costs of numerous life-saving medications by billions of dollars over the past few years, the Federal Trade Commission said in a report Tuesday.

In an interview on CNBC’s Mad Money, Len Schleifer said Regeneron (REGN) currently has 40 drugs in development representing billions in potential sales. “We know how to make and develop drugs ...